Martin Tolar

Current

Chief Business Officer at CoMentis Inc
Director, Board of Directors at Suven Life Sciences Ltd.

Past

Chief Scientific Officer at CoMentis Inc
Director, Worldwide Business Development at Pfizer
Vice President, Strategic and Corporate Development at CoMentis Inc

Assistant Professor at Yale University School of Medicine
Director, Neuroscience Clinical Development at Pfizer

see less...

2 more...

Connections

261 connections

Industry

Pharmaceuticals

Websites

My Company

Martin Tolar’s Summary

Martin Tolar, M.D., Ph.D., Chief Business Officer at CoMentis Inc

Dr. Tolar joined CoMentis in April 2007 as Vice President of Strategic and Corporate Development. He was promoted to Chief Scientific officer in October 2007 and following the signing of the collaboration agreement with Astellas Pharma in April 2008, to Chief Business Officer. In his current position Dr. Tolar is responsible for strategic business and corporate development activities.

Dr. Tolar has over 10 years of experience in the biopharmaceutical industry. He joined CoMentis from Pfizer, where he spent six years in a variety of leadership positions in Neuroscience Clinical Development, Alliance Management, and Business Development. As the Director of Worldwide Business Development, Dr. Tolar chaired the Neuroscience Licensing Team. He was responsible for licensing and outreach activities in Neurology and Psychiatry, including the 2006 acquisition of Rinat Neurosciences and the license of the RAGE platform from TransTech Pharma. Prior to his work in Neuroscience Licensing, Dr. Tolar served as the U.S. Clinical Leader for indiplon, an insomnia treatment developed with Neurocrine Biosciences, where he was responsible for the conduct of clinical trials and the NDA filings.

Dr. Tolar holds an M.D. degree and was trained in Neurology at the Boston Medical Center. In Boston, he also served as a Teaching Fellow in Neurology at Boston University’s School of Medicine and as a Research Fellow at Massachusetts General Hospital. Dr. Tolar received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease. From 2002 to 2007, Dr. Tolar held an appointment at Yale University School of Medicine, most recently as Assistant Professor in the Department of Neurology. He has published more than 20 scientific publications in the area of Neurosciences and serves on the Scientific Program Committee of the American Society for Experimental NeuroTherapeutics (ASENT).

Martin Tolar’s Experience

Chief Business Officer

CoMentis Inc

(Privately Held; 51-200 employees; Pharmaceuticals industry)

2008 — Present (less than a year)
Director, Board of Directors

Suven Life Sciences Ltd.

(Public Company; 201-500 employees; Pharmaceuticals industry)

2007 — Present (1 year)
Chief Scientific Officer

CoMentis Inc

(Privately Held; 51-200 employees; Biotechnology industry)

2007 — 2008 (1 year)
Director, Worldwide Business Development

Pfizer

(Public Company; 10,001 or more employees; PFE; Pharmaceuticals industry)

2005 — 2007 (2 years)

Director, Neuroscience Worldwide Business Development at Pfizer Inc
Vice President, Strategic and Corporate Development

CoMentis Inc

(Privately Held; 51-200 employees; Biotechnology industry)

2007 — 2007 (less than a year)
Assistant Professor

Yale University School of Medicine

(Educational Institution; 10,001 or more employees; Research industry)

2002 — 2007 (5 years)
Director, Neuroscience Clinical Development

Pfizer

(Public Company; 10,001 or more employees; PFE; Pharmaceuticals industry)

2001 — 2005 (4 years)